BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

728 related articles for article (PubMed ID: 30837276)

  • 1. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
    Xiao Y; Ma D; Zhao S; Suo C; Shi J; Xue MZ; Ruan M; Wang H; Zhao J; Li Q; Wang P; Shi L; Yang WT; Huang W; Hu X; Yu KD; Huang S; Bertucci F; Jiang YZ; Shao ZM;
    Clin Cancer Res; 2019 Aug; 25(16):5002-5014. PubMed ID: 30837276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
    Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
    Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a Gene Expression Signature to Predict the Risk of Early Recurrence and the Degree of Immune Cell Infiltration in Triple-negative Breast Cancer.
    Sato K; Miura K; Tamori S; Akimoto K
    Cancer Genomics Proteomics; 2024; 21(3):316-326. PubMed ID: 38670590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer.
    Yan Z; Zhong Z; Shi C; Feng M; Feng X; Liu T
    Cancer Biol Ther; 2024 Dec; 25(1):2355705. PubMed ID: 38778753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Profiles of Tumor Microenvironment and Clinical Prognosis among Women with Triple-Negative Breast Cancer.
    Deng L; Lu D; Bai Y; Wang Y; Bu H; Zheng H
    Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):1977-1985. PubMed ID: 31533938
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Chen Y; Huang Y; Gao X; Li Y; Lin J; Chen L; Chang L; Chen G; Guan Y; Pan LK; Xia X; Guo Z; Pan J; Xu Y; Yi X; Chen C
    Front Immunol; 2020; 11():1620. PubMed ID: 32903763
    [No Abstract]   [Full Text] [Related]  

  • 7. M1 Polarization Markers Are Upregulated in Basal-Like Breast Cancer Molecular Subtype and Associated With Favorable Patient Outcome.
    Hachim MY; Hachim IY; Talaat IM; Yakout NM; Hamoudi R
    Front Immunol; 2020; 11():560074. PubMed ID: 33304345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC.
    Bao X; Shi R; Zhao T; Wang Y; Anastasov N; Rosemann M; Fang W
    Cancer Immunol Immunother; 2021 Jan; 70(1):189-202. PubMed ID: 32681241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).
    Danaher P; Warren S; Lu R; Samayoa J; Sullivan A; Pekker I; Wallden B; Marincola FM; Cesano A
    J Immunother Cancer; 2018 Jun; 6(1):63. PubMed ID: 29929551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HGH1 and the immune landscape: a novel prognostic marker for immune-desert tumor microenvironment identification and immunotherapy outcome prediction in human cancers.
    Wu G; Dong Y; Hu Q; Ma H; Xu Q; Xu K; Chen H; Yang Z; He M
    Cell Cycle; 2023 Sep; 22(18):1969-1985. PubMed ID: 37811868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An exosome-based specific transcriptomic signature for profiling regulation patterns and modifying tumor immune microenvironment infiltration in triple-negative breast cancer.
    Wang H; Wang R; Luo L; Hong J; Chen X; Shen K; Wang Y; Huang R; Wang Z
    Front Immunol; 2023; 14():1295558. PubMed ID: 38124743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-Omics Pan-Cancer Analysis of Procollagen N-Propeptidase Gene Family of ADAMTS as Novel Biomarkers to Associate with Prognosis, Tumor Immune Microenvironment, Signaling Pathways, and Drug Sensitivities.
    Chen Y; Xiao C; Fan Q; Zhang Y; Huang Q; Ou Y
    Front Biosci (Landmark Ed); 2024 Apr; 29(4):151. PubMed ID: 38682182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of postoperative survival of triple-negative breast cancer based on nomogram model combined with expression of HIF-1α and c-myc.
    Cui J; Jiang H
    Medicine (Baltimore); 2019 Oct; 98(40):e17370. PubMed ID: 31577739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of CHD4-β1 integrin axis as a prognostic marker in triple-negative breast cancer using next-generation sequencing and bioinformatics.
    Ou-Yang F; Pan MR; Chang SJ; Wu CC; Fang SY; Li CL; Hou MF; Luo CW
    Life Sci; 2019 Dec; 238():116963. PubMed ID: 31639396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging.
    Keren L; Bosse M; Marquez D; Angoshtari R; Jain S; Varma S; Yang SR; Kurian A; Van Valen D; West R; Bendall SC; Angelo M
    Cell; 2018 Sep; 174(6):1373-1387.e19. PubMed ID: 30193111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and validation of neutrophils-related subtypes and prognosis model in triple negative breast cancer.
    Li S; Qian Y; Xie W; Li X; Wei J; Wang L; Ren G; Yin X
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):149. PubMed ID: 38512527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Immune Resistance Mechanisms in TNBC: Dual Effects Inside and Outside the Tumor.
    Xu J; Gan C; Yu S; Yao S; Li W; Cheng H
    Clin Breast Cancer; 2024 Feb; 24(2):e91-e102. PubMed ID: 38016911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a CD8
    Dai YW; Wang WM; Zhou X
    Heliyon; 2023 Sep; 9(9):e19798. PubMed ID: 37810147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case-control study.
    Yaghoobi V; Moutafi M; Aung TN; Pelekanou V; Yaghoubi S; Blenman K; Ibrahim E; Vathiotis IA; Shafi S; Sharma A; O'Meara T; Fernandez AI; Pusztai L; Rimm DL
    Breast Cancer Res; 2021 Dec; 23(1):113. PubMed ID: 34906209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relevance between hypoxia-dependent spatial transcriptomics and the prognosis and efficacy of immunotherapy in claudin-low breast cancer.
    Sun H; Li Y; Zhang Y; Zhao X; Dong X; Guo Y; Mo J; Che N; Ban X; Li F; Bai X; Li Y; Hao J; Zhang D
    Front Immunol; 2022; 13():1042835. PubMed ID: 36685583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.